Washington state has sued Novo Nordisk over how it marketed and priced Ozempic and Wegovy, and the case is now moving through court. This matters if you take, or hope to take, a GLP-1 drug, because a state attorney general is testing the same pricing claims that private plaintiffs have raised in other lawsuits. Several related cases against Novo Nordisk and Eli Lilly are also active. Together, they could shape what these drugs cost and what their labels say.
Washington's lawsuit against Novo Nordisk targets how the company marketed and priced Ozempic and Wegovy, and the state is asking the court for remedies that could include refunds or changes to pricing. Because this suit comes from a state attorney general rather than an individual patient, it carries more weight than a typical private claim, and a ruling against Novo Nordisk could set terms that reach beyond Washington. The case is active, with no ruling yet, so patients should not expect an immediate change in what they pay. Still, this is one to watch if drug cost is a concern for you.
A separate lawsuit, Milby v. Novo Nordisk, accuses the company of using unfair pricing and distribution practices to inflate what patients and insurers pay for Ozempic and Wegovy. If the claims hold up in court, the outcome could lower costs for people currently paying out of pocket or through insurance for these drugs. No ruling has been issued, and the substance of the allegations has not been fully tested, so this remains a possibility rather than a certainty. I would suggest keeping an eye on this case if pricing has been a barrier for you.
Eli Lilly is facing its own lawsuit, Ross v. Eli Lilly, which alleges the company used unfair pricing and misleading marketing for its GLP-1 drugs. This case is still working its way through court, and no findings have been made public yet. The allegations mirror those against Novo Nordisk, suggesting that pricing and marketing practices across the GLP-1 drug category are drawing similar scrutiny from plaintiffs. Patients taking Eli Lilly's GLP-1 medications may want to follow this case if they have questions about how the drug was marketed to them.
A different lawsuit against Eli Lilly, Eisbrouch v. Eli Lilly, focuses on the company's marketing and labeling rather than pricing alone. This case could reshape the guidance doctors receive when prescribing these drugs, and it could also affect what insurers decide to cover. Because labeling and marketing claims often influence how a drug is used in practice, a ruling here could have effects that reach beyond the parties named in the suit. The case remains active, and no outcome has been reported yet.
A third suit against Novo Nordisk, McDade v. Novo Nordisk, challenges the company's pricing and marketing practices and could affect both what patients pay and what information appears on drug labels. This case adds to a growing list of lawsuits raising similar concerns about Novo Nordisk's GLP-1 drugs, though each one proceeds on its own timeline and its own set of facts. Whether this particular case leads to changes in pricing or labeling will depend on how the court rules, and that has not yet happened. Patients relying on accurate label information may want to follow how this one develops.
None of these cases has reached a final ruling, so no immediate change in price or label language has taken effect. If you take a GLP-1 drug and are concerned about cost or about what the label tells you, it may help to talk with your pharmacist about current pricing options and to check with your insurer about coverage terms. You can also follow these cases directly through the links in each entry for updates as they move forward.
Key details
Washington sued Novo Nordisk, and a win could mean refunds or lower drug prices.
A lawsuit accusing Novo Nordisk of inflating prices could lower patient costs.
Eli Lilly faces a lawsuit alleging unfair pricing and misleading marketing.
Eli Lilly's marketing and labeling face a separate suit that could reshape coverage.
Another Novo Nordisk suit could affect what patients pay and label details.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.